Grp94 Inhibitor-1 (intraperitoneal injection,qid.; coadminbistration 10 mg/kg or 30 mg/kg; 8 days) does not attenuate the colon shortening, but decreases disease activity index (DAI) scores. It also TNFα and IL-6 levels in the serum and colonic tissues and significantly reduces the p65 expression in colonic tissues, especially those in the 30 mg/kg dose group[1].
| Animal Model: | C57BL/6 mice (male, 20-22 g)[1] |
| Dosage: | 10 mg/kg or 30 mg/kg |
| Administration: | Intraperitoneal injection,qid.; coadminbistration 10 mg/kg or 30 mg/kg |
| Result: | Decreased disease activity index (DAI) scores in UC mices. |
